Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210007/S008

Vivistim Paired VNS System

Mobia Medical, Inc. · Decision date Feb 26, 2026

FDA DECISIONP210007/S008

What did the FDA approve?

FDA records P210007/S008 as a supplement to PMA P210007, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Feb 26, 2026.

FDA approval order statement

Approval for expansion of MN Ops Center capabilities, including component receiving inspection & acceptance, in-house manufacturing and software installation of Stroke Application & Programming software (SAPS), routine software/firmware upgrades, and device relabeling.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Physical Medicine
Decision date
Feb 26, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P210007/S008
Regulatory pathway
PMA supplement
Product code
QPY
Decision code
APPR
Decision date
Feb 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for stroke rehabilitation.

Product code
QPY
FDA device class
3

For the original device and its historical approval scope, see PMA P210007. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210007/S008 received

    Application receipt date recorded by FDA.

  2. P210007/S008 · FDA decision

    Normal 180 Day Track

  3. P210007/S012 · Related supplement

    Vivistim Paired VNS System

  4. P210007/S014 · Related supplement

    Vivistim Pair VNS System

Timeline entries are records held by MedtechLedger for P210007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210007

Product / regulatory recordCompanyPathwayDecision dateSource
Mobia Medical, Inc.PMA approvalAug 27, 2021FDA
Vivistim SystemP210007/S007
Mobia Medical, Inc.PMA supplementSep 3, 2025FDA
Vivistim SystemP210007/S010
Mobia Medical, Inc.PMA supplementJan 28, 2026FDA
Vivistim SystemP210007/S011
Mobia Medical, Inc.PMA supplementMar 2, 2026FDA
Mobia Medical, Inc.PMA supplementApr 1, 2026FDA
Vivistim SystemP210007/S013
Mobia Medical, Inc.PMA supplementApr 10, 2026FDA
Mobia Medical, Inc.PMA supplementJun 18, 2026FDA
Vivistim SystemP210007/S015
Mobia Medical, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Mobia Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2802 Flintrock Trace, Suite 226, Austin, TX, 78738

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records